These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 31486418)
1. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer. Niu L; Gao Z; Cui Y; Yang X; Li H Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418 [TBL] [Abstract][Full Text] [Related]
2. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816 [TBL] [Abstract][Full Text] [Related]
3. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer. Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820 [TBL] [Abstract][Full Text] [Related]
4. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway. Lu R; Zhou Q; Ju L; Chen L; Wang F; Shao J Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184074 [TBL] [Abstract][Full Text] [Related]
5. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition. Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167 [TBL] [Abstract][Full Text] [Related]
6. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression. Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166 [TBL] [Abstract][Full Text] [Related]
7. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway. Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978 [TBL] [Abstract][Full Text] [Related]
8. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma. Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731 [TBL] [Abstract][Full Text] [Related]
9. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer. Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729 [TBL] [Abstract][Full Text] [Related]
10. TRIP13 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma. Di S; Li M; Ma Z; Guo K; Li X; Yan X Pathol Res Pract; 2019 Jun; 215(6):152415. PubMed ID: 31064720 [TBL] [Abstract][Full Text] [Related]
11. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma. Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476 [TBL] [Abstract][Full Text] [Related]
12. TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. Agarwal S; Behring M; Kim HG; Chandrashekar DS; Chakravarthi BVSK; Gupta N; Bajpai P; Elkholy A; Al Diffalha S; Datta PK; Heslin MJ; Varambally S; Manne U Mol Oncol; 2020 Dec; 14(12):3007-3029. PubMed ID: 33037736 [TBL] [Abstract][Full Text] [Related]
13. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway. Zhou XY; Shu XM Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159 [TBL] [Abstract][Full Text] [Related]
14. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development. Wu K; Zeng J; Zhou J; Fan J; Chen Y; Wang Z; Zhang T; Wang X; He D Urol Oncol; 2013 Nov; 31(8):1751-60. PubMed ID: 22421353 [TBL] [Abstract][Full Text] [Related]
15. Upregulation of NDRG1 predicts poor outcome and facilitates disease progression by influencing the EMT process in bladder cancer. Li A; Zhu X; Wang C; Yang S; Qiao Y; Qiao R; Zhang J Sci Rep; 2019 Mar; 9(1):5166. PubMed ID: 30914736 [TBL] [Abstract][Full Text] [Related]
16. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697 [TBL] [Abstract][Full Text] [Related]
17. HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc. Li Z; Liu J; Chen T; Sun R; Liu Z; Qiu B; Xu Y; Zhang Z J Exp Clin Cancer Res; 2021 Mar; 40(1):86. PubMed ID: 33648560 [TBL] [Abstract][Full Text] [Related]
18. MiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancer. Zhang X; Zhou J; Xue D; Li Z; Liu Y; Dong L Int J Biol Macromol; 2019 May; 129():227-232. PubMed ID: 30685303 [TBL] [Abstract][Full Text] [Related]
19. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer. Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944 [TBL] [Abstract][Full Text] [Related]
20. PCMT1 is an unfavorable predictor and functions as an oncogene in bladder cancer. Dong L; Li Y; Xue D; Liu Y IUBMB Life; 2018 Apr; 70(4):291-299. PubMed ID: 29517839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]